AOMA Summit 2022

Australasia's premier ocular melanoma cross-disciplinary meeting

The 2022 Australasian Ocular Melanoma Alliance (AOMA) Summit was an all-day online meeting that was held on Saturday 30 July 2022. Videos of the sessions are below.

We had 200 people register for the event, including ophthalmologists, medical oncologists, radiation oncologists, pathologists, medical researchers, patients and consumer advocates. The online format allowed people to attend from all over the world, including the USA, UK, Ireland, New Zealand and Poland.

Facilitating collaborations for ocular melanoma

Building on the previously highly successful Australasian Ocular Melanoma Alliance (AOMA) summits, the 3rd AOMA Summit in July 2022 brought together healthcare professionals, researchers and consumers in ocular melanoma to facilitate national and international collaborations for this rare, debilitating and often devastating cancer.

This virtual event included a scientific program and presentations focused on consumer and advocate involvement.

The AOMA Summit covered diagnosis and clinical management, clinical trials and registries, laboratory and translational research, current and future treatment options, and consumer and clinician discussion panels.

The annual AOMA Summit is the premier ocular melanoma cross-disciplinary meeting in Australasia.

International speakers

  • Prof Sarah Coupland, Professor and Honorary Consultant in Pathology at the Liverpool Ocular Oncology Research Group, University of Liverpool, UK
  • Prof Heinrich Heimann, Consultant Ophthalmic Surgeon at the Liverpool Ocular Oncology Centre, UK
  • Prof Mandeep S. Sagoo, Professor of Ophthalmology and Ocular Oncology at UCL and Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, 
    London, UK
  • Dr Paul Nathan, Consultant Medical Oncologist at Mount Vernon Cancer Centre, UK
  • Mr Sachin Salvi, Consultant Ophthalmologist and Ocular Oncologist at Sheffield Ocular Oncology Service, Royal Hallamshire Hospital, UK 
  • Dr Amanda Deisher, Radiation Oncology Consultant at Mayo Clinic, USA
  • Dr Lauren Dalvin, Ocular Oncologist and A/Prof of Ophthalmology at Mayo Clinic, USA
  • Dr David J. Eschelman, Professor of Radiology and Co-Director of Interventional Radiology and the Metastatic Uveal Melanoma Multidisciplinary Center at Thomas Jefferson University Hospital, USA

Australian speakers

  • Dr John McKenzie, Ophthalmologist at Royal Victorian Eye and Ear Hospital
  • Dr Rod O’Day, Ocular Oncology and Medical Retina Subspecialist at the Royal Victorian Eye and Ear Hospital and Head of Ocular Oncology Research at the Centre for Eye Research Australia
  • Ms Camille Loyer, Ocularist at Loyer Artificial Eyes
  • A/Prof Penny McKelvie, Anatomical Pathologist at St Vincent’s Hospital Melbourne
  • Prof Jonas Nilsson, Professor of Melanoma Discovery at Harry Perkins Institute of Medical Research and Professor in Experimental Cancer Surgery, University of Gothenburg, Sweden
  • Dr Lotte S. Fog, Medical Physicist at The Alfred Hospital and Royal Victorian Eye and Ear Hospital
  • Dr Peter Johansson, Research Scientist, Oncogenomics Group at QIMR Berghofer
  • Dr Aaron Beasley, Early Career Researcher at the Centre for Precision Health, Edith Cowan University
  • Prof Mark Shackleton, Board Chair of Melanoma and Skin Cancer Trials, Director of Oncology at Alfred Health, Professor of Oncology at Monash University, Director of Cancer Trials Australia, and a Victorian Cancer Agency Clinical Research Fellow
  • Dr Tim Luckett – Senior Lecturer with IMPACCT (Improving Palliative, Aged and Chronic Care through Clinical Research and Translation), University of Technology Sydney
  • Neil Vincent – consumer
  • Jessica Rowe – consumer 

AOMA Summit organising committee

  • Prof Anthony Joshua, Medical Oncologist at St Vincent’s Private Hospital Sydney, Clinical Science Pillar Director and Lab Head – Oncology Translational Research Laboratory, at Garvan Institute of Medical Research
  • Dr Damien Kee, Medical Oncologist at the Austin Hospital and Peter MacCallum Cancer Centre
  • Dr Daniel McKay, Ophthalmologist and Ocular Oncologist at Royal Victorian Eye and Ear Hospital, Monash Health and Eastern Health
  • Dr Claire Phillips, Deputy Director and NeuroOncology Lead for the Department of Radiation Oncology at the Peter MacCallum Cancer Centre
  • Gabrielle Byars, CEO at Melanoma and Skin Cancer Trials
  • Merrin Morrison, Marketing and Communications Manager at Melanoma and Skin Cancer Trials
  • Ayeshini Sella Hewage, Clinical Trials Assistant at Melanoma and Skin Cancer Trials
  • Elizabeth Sadowey, Executive Assistant / Senior Officer Administrator at Melanoma and Skin Cancer Trials

Australasian Ocular Melanoma Alliance (AOMA)

The Australasian Ocular Melanoma Alliance (AOMA) is the peak national body representing medical, para-medical, nursing and consumer representatives who aim to improve the care and treatment of ocular melanoma patients in Australia and around the world.

AOMA members include Ophthalmologists, Surgeons, Medical and Radiation Oncologists, Pathologists, Allied Health, Scientists, Researchers and Consumer Representatives from across Australia and New Zealand. The focus of this extensive collaboration is treatment paradigms for ocular melanoma, and current and future research.

AOMA was founded in 2017 by Melanoma and Skin Cancer Trials (MASC Trials) and is a MASC Trials priority research special interest group.

Visit the AOMA website for more information.


Patient information brochures about early and advanced ocular melanoma are now available through Melanoma Institute Australia and AOMA. 

Uveal Melanoma Registry 
Gathering data to improve clinical practice for uveal melanoma.
Learn more.


AOMA news


Phone: +61 3 9903 9022

Follow AOMA on Twitter

Read MASC Trials news

AOMA Summit 2022 Sponsors